



United States Patent [19]
Stashenko et al.

[11] Patent Number: 5,552,281
[45] Date of Patent: Sep. 3, 1996

[54] HUMAN OSTEOCLAST-SPECIFIC AND
-RELATED GENES

[75] Inventors: Philip Stashenko, Norfolk; Yi-Ping Li,
Boston; Anne L. Wucherpfennig,
Brookline, all of Mass.

[73] Assignee: Forsyth Dental Infirmary for
Children, Boston, Mass.

[21] Appl. No.: 392,678

[22] Filed: Feb. 23, 1995

Related U.S. Application Data

[63] Continuation of Ser. No. 45,270, Apr. 6, 1993, abandoned.

[51] Int. Cl.⁶ C07H 21/04; C12N 5/10;
C12N 15/70; C12Q 1/68

[52] U.S. Cl. 435/6; 435/69.1; 435/172.3;
435/252.3; 435/320.1; 536/23.1

[58] Field of Search 435/6, 320.1, 252.3,
435/69.1, 172.3; 536/23.1

[56] References Cited
PUBLICATIONS

Blair, Harry C., et al., "Extracellular-matrix degradation at acid pH. Avian osteoclast acid collagenase isolation and characterization", *Biochemical Journal* 290(3):873-884 (15 Mar. 1993).

Tezuka, Ken-Ichi, et al., "Identification of osteopontin in isolated rabbit osteoclasts", *Biochemical and Biophysical Research Communications* 186(2):914-916 (31 Jul. 1992).

Tezuka, Ken-Ichi, et al., "Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts", *Journal of Biological Chemistry* 269(2):1106-1108, (14 Jan. 1994).

Horton, Michael A. et al., "Monoclonal Antibodies to Osteoclastomas (Giant Cell Bone Tumors): Definition of Osteoclast-specific Cellular Antigens," *Cancer Research* 45, 5663-5669 (Nov. 1985).

Davies, John et al., "The Osteoclast Functional Antigen, Implicated in the Regulation of Bone Resorption, Is Biochemically Related to the Vitronectin Receptor," *The Journal of Cell Biology* 109, 1817-1826 (Oct. 1989).

Hayman, Alison, R. et al., "Purification and characterization of a tartrate-resistant acid phosphatase from human osteoclastomas," *Biochem. J.* 261, 601-609 (1989).

Sandberg, M. et al., "Localization of the Expression of Types I, III, and IV Collagen, TGF- β 1 and c-fos Genes in Developing Human Calvarial Bones," *Developmental Biology* 130, 324-334 (1988).

Sandberg, M. et al., "Enhanced expression of TGF- β and c-fos mRNAs in the growth plates of developing human long bones," *Development* 102, 461-470 (1988).

Ek-Rylander, Barbro et al., "Cloning, Sequence, and Developmental Expression of a Type 5, Tartrate-resistant, Acid Phosphatase of Rat Bone," *The Journal of Biological Chemistry* 266(36), 24684-24689 (Dec. 25, 1991).

GenBank/EMBL Sequence Search Printout, pp. 1-19 (Jun. 24, 1993).

Primary Examiner—W. Gary Jones

Assistant Examiner—Paul B. Tran

Attorney, Agent, or Firm—Hamilton, Brook, Smith & Reynolds, P.C.

[57] ABSTRACT

The present invention relates to purified DNA sequences encoding all or a portion of an osteoclast-specific or -related gene products and a method for identifying such sequences. The invention also relates to antibodies directed against an osteoclast-specific or -related gene product. Also claimed are DNA constructs capable of replicating DNA encoding all or a portion of an osteoclast-specific or -related gene product, and DNA constructs capable of directing expression in a host cell of an osteoclast-specific or -related gene product.

5 Claims, 1 Drawing Sheet

1 AACATCTT GGGTGGG TGGGCTT GAGGCTT GTTGTGTC TGTGCTT
2 GGTGCTT GTTGTGTC TGTGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
3 GTTGTGTC TGTGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
4 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
5 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
6 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
7 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
8 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
9 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
10 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
11 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
12 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
13 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
14 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
15 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
16 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
17 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
18 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
19 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
20 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
21 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
22 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
23 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
24 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
25 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
26 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
27 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
28 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
29 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
30 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
31 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
32 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
33 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
34 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
35 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
36 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
37 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
38 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
39 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
40 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
41 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
42 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
43 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
44 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
45 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
46 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
47 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
48 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
49 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
50 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
51 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
52 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
53 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
54 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
55 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
56 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
57 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
58 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
59 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
60 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
61 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
62 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
63 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
64 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
65 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
66 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
67 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
68 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
69 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
70 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
71 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
72 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
73 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
74 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
75 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
76 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
77 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
78 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
79 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
80 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
81 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
82 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
83 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
84 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
85 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
86 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
87 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
88 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
89 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
90 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
91 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
92 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
93 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
94 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
95 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
96 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
97 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
98 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
99 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT
100 GAGGCTT GAGGCTT GAGGCTT GAGGCTT GAGGCTT GTTGTGTC TGTGCTT

1 AGACACCTCT GCCCTCACCA TGAGCCTCTG GCAGCCCCTG GTCCTGGTGC TCCTGGTGCT
61 GGGCTGCTGC TTTGCTGCCC CCAGACAGCG CCAGTCCACC CTTGTGCTCT TCCCTGGAGA
121 CCTGAGAACC AATCTCACCG ACAGGCAGCT GGCAGAGGAA TACCTGTACC GCTATGGTTA
181 CACTCGGGTG GCAGAGATGC GTGGAGAGTC GAAATCTCTG GGGCCTGCGC TGCTGCTTCT
241 CCAGAAGCAA CTGTCCCTGC CCGAGACCAG TGAGCTGGAT AGCGCCACGC TGAAGGCCAT
301 GCGAACCCCA CGGTGCGGGG TCCAGACCT GGGCAGATT CAAACCTTTG AGGGCGACCT
361 CAAGTGGCAC CACCACAACA TCACCTATTG GATCCAAAAC TACTCGGAAG ACTTGCCCGC
421 GGCAGGTGATT GACGACGCCT TTGCCCAGCG CTTGCACTG TGAGCGCGG TGACGCCGCT
481 CACCTTCACT CGCGTGACA GCCGGGACGC AGACATCGTC ATCCAGTTTG GTGTCGCGGA
541 GCACGGAGAC GGGTATCCCT TCGACGGGAA GGACGGGCTC CTGGCACACG CCTTTCCTCC
601 TGGCCCCGGC ATTCAGGGAG ACGCCATT TCGACGATGAC GAGTTGTGGT CCCTGGGCAA
661 GGCGTCTGTT GTTCCAATC GGTTTGGAAA CGCAGATGGC GCGGCCTGCC ACTTCCCTT
721 CATCTTCGAG GCGCGCTCCT ACTCTGCTG CACCACCGAC GGTGCTCCG ACGGGTTGCC
781 CTGGTGCACT ACCACGGCCA ACTACGACAC CGACGACCGG TTTGGCTTCT GCCCAGCGA
841 GAGACTCTAC ACCCGGGACG GCAATGCTGA TGGGAAACCC TGCCAGTTTC CATTCATCTT
901 CCAAGGCCAA TCCTACTCCG CTTGCACAC GGACGGTCCG TCCGACGGCT ACCGCTGGT
961 CGCCACCAAC GCCAACTACG ACCGGGACAA GCTCTTCGGC TTCTGCCCGA CCCGAGCTGA
1021 CTCGACGGTG ATGGGGGGCA ACTCGGCGGG GGAGCTGTGC GTCTTCCCCT TCACCTTCT
1081 GGGTAAGGAG TACTCGACCT GTACCAGCGA GGGCCGCGGA GATGGGCGCC TCTGGTGCGC
1141 TACCACCTCG AACTTTGACA GCGACAAGAA GTGGGGCTTC TGCCCGGACC AAGGATACAG
1201 TTGTTCCTC GTGGCGGCGC ATGAGTTCGG CCACGCGCTG GGCTTAGATC ATTCCTCAGT
1261 GCCGGAGGCG CTCATGTACC CTATGTACCG CTTCACTGAG GGGCCCCCTT TGCATAAGGA
1321 CGACGTGAAT GGCATCCGCG ACCTCTATGG TCCTCGCCCT GAACCTGAGC CACGGCCTCC
1381 AACCACCACC ACACCGCAGC CCACGGCTCC CCGACGGTC TGCCCCACCG GACCCCCAC
1441 TGTCCACCCC TCAGAGCGCC CCACAGCTGG CCCCACAGGT CCCCCCTCAG CTGGCCCCAC
1501 AGGTCCCCC ACTGCTGGCC CTTCTACGGC CACTACTGTG CTTTGTAGTC CGGTGGACGA
1561 TGCTGCAAC GTGAACATCT TCGACGCCAT CGCGGAGATT GGGAAACCAGC TGTATTGT
1621 CAAGGATGGG AAGTACTGGC GATTCTCTGA GGGCAGGGG AGCCGGCCGC AGGGCCCCCT
1681 CCTTATCGCC GACAAGTGGC CCGCGCTGCC CCGCAAGCTG GACTCGGTCT TTGAGGAGCC
1741 GCTCTCCAAG AAGCTTTCT TCTTCTCTG GCGCCAGGTG TGGGTGTACA CAGGCGCGTC
1801 GGTGCTGGG CCGAGGCGTC TGGACAAGCT GGGCCTGGGA GCCGACGTGG CCCAGGTGAC
1861 CGGGGCCCTC CGGAGTGGCA GGGGGAAGAT GCTGCTGTT AGCGGGCGGC GCCTCTGGAG
1921 GTTCGACGTG AAGGCGCAGA TGGTGGATCC CCGGAGCGCC AGCGAGGTGG ACCGGATGTT
1981 CCCCGGGGTG CCTTTGGACA CGCAGGACGT CTTCCAGTAC CGAGAGAAAG CCTATTTCTG
2041 CCAGGACCGC TTCTACTGGC GCGTGAGTTC CCGGAGTGAG TTGAACCAGG TGGACCAAGT
2101 GGGCTACGTG ACCTATGACA TCCTGCAGTG CCCTGAGGAC TAGGGCTCCC GTCCTGCTTT
2161 GCAGTGCCAT GTAAATCCCC ACTGGGACCA ACCCTGGGGA AGGAGCCAGT TTGCCGGATA
2221 CAAACCTGTA TTCTGTCTG GAGGAAAGG AGGAGTGGAG GTGGGCTGGG CCCTCTCTTC
2281 TCACCTTGT TTTTGTGG AGTGTCTTA ATAACTGG ATTCTCTAAC CTTT

Figure 1

HUMAN OSTEOCLAST-SPECIFIC AND -RELATED GENES

RELATED APPLICATION

This application is a continuation of application Ser. No. 08/045,270 filed on Apr. 6, 1993 now abandoned.

BACKGROUND OF THE INVENTION

Excessive bone resorption by osteoclasts contributes to the pathology of many human diseases including arthritis, osteoporosis, periodontitis, and hypercalcemia of malignancy. During resorption, osteoclasts remove both the mineral and organic components of bone (Blair, H. C., et al., *J. Cell Biol.* 102:1164 (1986)). The mineral phase is solubilized by acidification of the sub-osteoclastic lacuna, thus allowing dissolution of hydroxyapatite (Vaes, G., *Clin. Orthop. Relat.* 231:239 (1988)). However, the mechanism(s) by which type I collagen, the major structural protein of bone, is degraded remains controversial. In addition, the regulation of osteoclastic activity is only partly understood. The lack of information concerning osteoclast function is due in part to the fact that these cells are extremely difficult to isolate as pure populations in large numbers. Furthermore, there are no osteoclastic cell lines available. An approach to studying osteoclast function that permits the identification of heretofore unknown osteoclast-specific or -related genes and gene products would allow identification of genes and gene products that are involved in the resorption of bone and in the regulation of osteoclastic activity. Therefore, identification of osteoclast-specific or -related genes or gene products would prove useful in developing therapeutic strategies for the treatment of disorders involving aberrant bone resorption.

SUMMARY OF THE INVENTION

The present invention relates to isolated DNA sequences encoding all or a portion of osteoclast-specific or -related gene products. The present invention further relates to DNA constructs capable of replicating DNA encoding osteoclast-specific or -related gene products. In another embodiment, the invention relates to a DNA construct capable of directing expression of all or a portion of the osteoclast-specific or -related gene product in a host cell.

Also encompassed by the present invention are prokaryotic or eukaryotic cells transformed or transfected with a DNA construct encoding all or a portion of an osteoclast-specific or -related gene product. According to a particular embodiment, these cells are capable of replicating the DNA construct comprising the DNA encoding the osteoclast-specific or -related gene product, and, optionally, are capable of expressing the osteoclast-specific or -related gene product. Also claimed are antibodies raised against osteoclast-specific or -related gene products, or portions of these gene products.

The present invention further embraces a method of identifying osteoclast-specific or -related DNA sequences and DNA sequences identified in this manner. In one embodiment, cDNA encoding osteoclast is identified as follows: First, human giant cell tumor of the bone was used to 1) construct a cDNA library; 2) produce ³²P-labelled cDNA to use as a stromal cell⁺; osteoclast⁺ probe, and 3) produce (by culturing) a stromal cell population lacking osteoclasts. The presence of osteoclasts in the giant cell tumor was confirmed by histological staining for the osteo-

clast marker, type 5 tartrate-resistant acid phosphatase (TRAP) and with the use of monoclonal antibody reagents.

The stromal cell population lacking osteoclasts was produced by dissociating cells of a giant cell tumor, then growing and passaging the cells in tissue culture until the cell population was homogeneous and appeared fibroblastic. The cultured stromal cell population did not contain osteoclasts. The cultured stromal cells were then used to produce a stromal cell⁺, osteoclast⁻ ³²P-labelled cDNA probe.

The cDNA library produced from the giant cell tumor of the bone was then screened in duplicate for hybridization to the cDNA probes: one screen was performed with the giant cell tumor cDNA probe (stromal cell⁺, osteoclast⁺), while a duplicate screen was performed using the cultured stromal cell cDNA probe (stromal cell⁺, osteoclast⁻). Hybridization to a stromal⁺, osteoclast⁺ probe, accompanied by failure to hybridize to a stromal⁺, osteoclast⁻ probe indicated that a clone contained nucleic acid sequences specifically expressed by osteoclasts.

In another embodiment, genomic DNA encoding osteoclast-specific or -related gene products is identified through known hybridization techniques or amplification techniques. In one embodiment, the present invention relates to a method of identifying DNA encoding an osteoclast-specific or -related protein, or gene product, by screening a cDNA library or a genomic DNA library with a DNA probe comprising one or more sequences selected from the group consisting of the DNA sequences set out in Table I (SEQ ID NOs: 1-32). Finally, the present invention relates to an osteoclast-specific or related protein encoded by a nucleotide sequence comprising a DNA sequence selected from the group consisting of the sequences set out in Table I, or their complementary strands.

BRIEF DESCRIPTION OF FIG. 1

The FIG. 1 shows cDNA sequence (SEQ ID NO: 33) of human gelatinase B, and highlights those portions of the sequence represented by the osteoclast-specific or -related cDNA clones of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

As described herein, Applicant has identified osteoclast-specific or osteoclast-related nucleic acid sequences. These sequences were identified as follows: Human giant cell tumor of the bone was used to 1) construct a cDNA library; 2) produce ³²P-labelled cDNA to use as a stromal cell⁺, osteoclast⁺ probe, and 3) produce (by culturing) a stromal cell population lacking osteoclasts. The presence of osteoclasts in the giant cell tumor was confirmed by histological staining for the osteoclast marker, type 5 acid phosphatase (TRAP). In addition, monoclonal antibody reagents were used to characterize the multinucleated cells in the giant cell tumor, which cells were found to have a phenotype distinct from macrophages and consistent with osteoclasts.

The stromal cell population lacking osteoclasts was produced by dissociating cells of a giant cell tumor, then growing the cells in tissue culture for at least five passages. After five passages the cultured cell population was homogeneous and appeared fibroblastic. The cultured population contained no multinucleated cells at this point, tested negative for type 5 acid phosphatase, and tested variably alkaline phosphatase positive. That is, the cultured stromal cell population did not contain osteoclasts. The cultured stromal

cells were then used to produce a stromal cell⁺, osteoclast⁻ ³²P-labelled cDNA probe.

The cDNA library produced from the giant cell tumor of the bone was then screened in duplicate for hybridization to the cDNA probes: one screen was performed with the giant cell tumor cDNA probe (stromal cell⁺, osteoclast⁺), while a duplicate screen was performed using the cultured stromal cell cDNA probe (stromal cell⁺ osteoclast⁻). Clones that hybridized to the giant cell tumor cDNA probe (stromal⁺, osteoclast⁺), but not to the stromal cell cDNA probe (stromal⁺, osteoclast⁻), were assumed to contain nucleic acid sequences specifically expressed by osteoclasts.

As a result of the differential screen described herein, DNA specifically expressed in osteoclast cells characterized as described herein was identified. This DNA, and equivalent DNA sequences, is referred to herein as osteoclast-specific or osteoclast-related DNA. Osteoclast-specific or -related DNA of the present invention can be obtained from sources in which it occurs in nature, can be produced recombinantly or synthesized chemically; it can be cDNA, genomic DNA, recombinantly-produced DNA or chemically-produced DNA. An equivalent DNA sequence is one which hybridizes, under standard hybridization conditions, to an osteoclast-specific or -related DNA identified as described herein or to a complement thereof.

Differential screening of a human osteoclastoma cDNA library was performed to identify genes specifically expressed in osteoclasts. Of 12,000 clones screened, 195 clones were identified which are either uniquely expressed in osteoclasts, or are osteoclast-related. These clones were further identified as osteoclast-specific, as evidenced by failure to hybridize to mRNA derived from a variety of unrelated human cell types, including epithelium, fibroblasts, lymphocytes, myelomonocytic cells, osteoblasts, and neuroblastoma cells. Of these, 32 clones contain novel cDNA sequences which were not found in the GenBank database.

A large number of cDNA clones obtained by this procedure were found to represent 92 kDa type IV collagenase (gelatinase B; E.C. 3.4.24.35) as well as tartrate resistant acid phosphatase. In situ hybridization localized mRNA for gelatinase B to multinucleated giant cells in human osteoclastomas. Gelatinase B immunoreactivity was demonstrated in giant cells from 8/8 osteoclastomas, osteoclasts in normal bone, and in osteoclasts of Paget's disease by use of a polyclonal antiserum raised against a synthetic gelatinase B peptide. In contrast, no immunoreactivity for 72 kDa type IV collagenase (gelatinase A; E.C. 3.4.24.24), which is the product of a separate gene, was detected in osteoclastomas or normal osteoclasts.

The present invention has utility for the production and identification of nucleic acid probes useful for identifying osteoclast-specific or -related DNA. Osteoclast-specific or -related DNA of the present invention can be used to produce osteoclast-specific or -related gene products useful in the therapeutic treatment of disorders involving aberrant bone resorption. The osteoclast-specific or -related sequences are also useful for generating peptides which can then be used to produce antibodies useful for identifying osteoclast-specific or -related gene products, or for altering the activity of osteoclast-specific or -related gene products. Such antibodies are referred to as osteoclast-specific antibodies. Osteoclast-specific antibodies are also useful for identifying osteoclasts. Finally, osteoclast -specific or -related DNA sequences of the present invention are useful in gene therapy. For example, they can be used to alter the

expression in osteoclasts of an aberrant osteoclast -specific or -related gene product or to correct aberrant expression of an osteoclast-specific or -related gene product. The sequences described herein can further be used to cause osteoclast-specific or related gene expression in cells in which such expression does not ordinarily occur, i.e., in cells which are not osteoclasts.

Example 1—Osteoclast cDNA Library Construction

Messenger RNA (mRNA) obtained from a human osteoclastoma ('giant cell tumor of bone'), was used to construct an osteoclastoma cDNA library. Osteoclastomas are actively bone resorptive tumors, but are usually non-metastatic. In cryostat sections, osteoclastomas consist of ~30% multinucleated cells positive for tartrate resistant acid phosphatase (TRAP), a widely utilized phenotypic marker specific in vivo for osteoclasts (Minkin, *Calcif. Tissue Int.* 34:285-290 (1982)). The remaining cells are uncharacterized 'stromal' cells, a mixture of cell types with fibroblastic/mesenchymal morphology. Although it has not yet been definitively shown, it is generally held that the osteoclasts in these tumors are non-transformed, and are activated to resorb bone in vivo by substance(s) produced by the stromal cell element.

Monoclonal antibody reagents were used to partially characterize the surface phenotype of the multinucleated cells in the giant cell tumors of long bone. In frozen sections, all multinucleated cells expressed CD68, which has previously been reported to define an antigen specific for both osteoclasts and macrophages (Horton, M. A. and M. H. Helfrich, In *Biology and Physiology of the Osteoclast*, B. R. Rifkin and C. V. Gay, editors, CRC Press, Inc. Boca Raton, Fla., 33-54 (1992)). In contrast, no staining of giant cells was observed for CD11b or CD14 surface antigens, which are present on monocyte/macrophages and granulocytes (Araout, M. A. et al. *J. Cell. Physiol.* 137:305 (1988); Haziot, A. et al. *J. Immunol.* 141:547 (1988)). Cytocentrifuge preparations of human peripheral blood monocytes were positive for CD68, CD11b, and CD14. These results demonstrate that the multinucleated giant cells of osteoclastomas have a phenotype which is distinct from that of macrophages, and which is consistent with that of osteoclasts.

Osteoclastoma tissue was snap frozen in liquid nitrogen and used to prepare poly A⁺ mRNA according to standard methods. cDNA cloning into a pcDNAII vector was carried out using a commercially-available kit (Librarian, InVitrogen). Approximately 2.6×10⁶ clones were obtained, >95% of which contained inserts of an average length 0.6 kB.

Example 2—Stromal Cell mRNA Preparation

A portion of each osteoclastoma was snap frozen in liquid nitrogen for mRNA preparation. The remainder of the tumor was dissociated using brief trypsinization and mechanical disaggregation, and placed into tissue culture. These cells were expanded in Dulbecco's MEM (high glucose, Sigma) supplemented with 10% newborn calf serum (MA Bioproducts), gentamycin (0.5 mg/ml), l-glutamine (2 mM) and non-essential amino acids (0.1 mM) (Gibco). The stromal cell population was passaged at least five times, after which it showed a homogenous, fibroblastic looking cell population that contained no multinucleated cells. The stromal cells were mononuclear, tested negative acid phosphatase, and tested variably alkaline phosphatase positive. These findings indicate that propagated stromal cells (i.e., stromal cells that

are passaged in culture) are non-osteoclastic and non-activated.

Example 3—Identification of DNA Encoding Osteoclastoma-Specific or -Related Gene Products by Differential screening of an Osteoclastoma cDNA Library

A total of 12,000 clones drawn from the osteoclastoma cDNA library were screened by differential hybridization, using mixed ^{32}P labelled cDNA probes derived from (1) giant cell tumor mRNA (stromal cell⁺, OC⁺), and (2) mRNA from stromal cells (stromal cell⁺, OC⁺) cultivated from the same tumor. The probes were labelled with ^{32}P dCTP by random priming to an activity of $\sim 10^6\text{CPM}/\mu\text{g}$. Of these 12,000 clones, 195 gave a positive hybridization signal with giant cell (i.e., osteoclast and stromal cell) mRNA, but not with stromal cell mRNA. Additionally, these clones failed to hybridize to cDNA produced from mRNA derived from a variety of unrelated human cell types including epithelial cells, fibroblasts, lymphocytes, myelomonocytic cells, osteoblasts, and neuroblastoma cells. The failure of these clones to hybridize to cDNA produced from mRNA derived from other cell types supports the conclusion that these clones are either uniquely expressed in osteoclasts, or are osteoclast-related.

The osteoclast (OC) cDNA library was screened for differential hybridization to OC cDNA (stromal cell⁺, OC⁺) and stromal cell cDNA (stromal cell⁺, OC⁺) as follows:

NYTRAN filters (Schleicher & Schuell) were placed on agar plates containing growth medium and ampicillin. Individual bacterial colonies from the OC library were randomly picked and transferred, in triplicate, onto filters with preruled grids and then onto a master agar plate. Up to 200 colonies were inoculated onto a single 90-mm filter/plate using these techniques. The plates were inverted and incubated at 37° C. until the bacterial inoculates had grown (on the filter) to a diameter of 0.5–1.0 mm.

The colonies were then lysed, and the DNA bound to the filters by first placing the filters on top of two pieces of Whatman 3 MM paper saturated with 0.5N NaOH for 5 minutes. The filters were neutralized by placing on two pieces of Whatman 3 MM paper saturated with 1M Tris-HCL, pH 8.0 for 3–5 minutes. Neutralization was followed by incubation on another set of Whatman 3 MM papers saturated with 1M Tris-HCL, pH 8.0/1.5M NaCl for 3–5 minutes. The filters were then washed briefly in 2xSSC.

DNA was immobilized on the filters by baking the filters at 80° C. for 30 minutes. Filters were best used immediately, but they could be stored for up to one week in a vacuum jar at room temperature.

Filters were prehybridized in 5–8 ml of hybridization solution per filter, for 2–4 hours in a heat sealable bag. An additional 2 ml of solution was added for each additional filter added to the hybridization bag. The hybridization

buffer consisted of 5xSSC, 5xDenhardt's solution, 1% SDS and 100 $\mu\text{g}/\text{ml}$ denatured heterologous DNA.

Prior to hybridization, labeled probe was denatured by heating in 1xSSC for 5 minutes at 100° C., then immediately chilled on ice. Denatured probe was added to the filters in hybridization solution, and the filters hybridized with continuous agitation for 12–20 hours at 65° C.

After hybridization, the filters were washed in 2xSSC/0.2% SDS at 50°–60° C. for 30 minutes, followed by washing in 0.2xSSC/0.2% SDS at 60° C. for 60 minutes.

The filters were then air dried and autoradiographed using an intensifying screen at –70° C. overnight.

Example 4—DNA Sequencing of Selected Clones

Clones reactive with the mixed tumor probe, but unreactive with the stromal cell probe, are expected to contain either osteoclast-related, or in vivo 'activated' stromal-cell-related gene products. One hundred and forty-four cDNA clones that hybridized to tumor cell cDNA, but not to stromal cell cDNA, were sequenced by the dideoxy chain termination method of Sanger et al. (Sanger F., et al. *Proc. Natl. Acad. Sci. USA* 74:5463 (1977)) using sequenase (US Biochemical). The DNASIS (Hitachi) program was used to carry out sequence analysis and a homology search in the GenBank/EMBL database.

Fourteen of the 195 tumor⁺ stromal[–] clones were identified as containing inserts with a sequence identical to the osteoclast marker, type 5 tartrate-resistant acid phosphatase (TRAP) (GenBank accession number J04430 M19534). The high representation of TRAP positive clones also indicates the effectiveness of the screening procedure in enriching for clones which contain osteoclast-specific or related cDNA sequences.

Interestingly, an even larger proportion of the tumor⁺ stromal[–] clones (77/195; 39.5%) were identified as human gelatinase B (macrophage-derived gelatinase) (Wilhelm, S. M. *J. Biol. Chem.* 264:17213 (1989)), again indicating high expression of this enzyme by osteoclasts. Twenty-five of the gelatinase B clones were identified by dideoxy sequence analysis; all 25 showed 100% sequence homology to the published gelatinase B sequence (Genbank accession number J05070). The portions of the gelatinase B cDNA sequence covered by these clones is shown in the FIGURE (SEQ ID NO: 33). An additional 52 gelatinase B clones were identified by reactivity with a ^{32}P -labelled probe for gelatinase B.

Thirteen of the sequenced clones yielded no readable sequence. A DNASIS search of GenBank/EMBL databases revealed that, of the remaining 91 clones, 32 clones contain novel sequences which have not yet been reported in the databases or in the literature. These partial sequences are presented in Table I. Note that three of these sequences were repeats, indicating fairly frequent representation of mRNA related to this sequence. The repeat sequences are indicated by ^a, ^b superscripts (Clones 198B, 223B and 32C of Table I).

TABLE I

PARTIAL SEQUENCES OF 32 NOVEL OC-SPECIFIC OR -RELATED EXPRESSED GENES (cDNA CLONES)

34A (SEQ ID NO: 1)	AAGTTTATTC	CTTGGATTTC	TATGAGAGC	TGTTGAATT	GGTGATGTCA
1 GCAAATATCT	GGGTTTTTTT	AGTTTGTITT	TATTGAAAAA	TTTAATTATT	TATGCTATAG
61 AATGTTTCTA	CTTTGAATAA	ACCTATAATA	GAAATATGCA	GCAGACAACA	
121 GTGATAATCT					
4B (SEQ ID NO: 2)					
1 GTGTCAACCT	GCATATCTTA	AAAATGTCAA	AATGCTGCAT	CTGGTTAATG	TCGGGGTAGG

TABLE I-continued

PARTIAL SEQUENCES OF 32 NOVEL OC-SPECIFIC OR -RELATED
EXPRESSED GENES (cDNA CLONES)

61	GGG					
12B (SEQ ID NO: 3)						
1	CTTCCCTCTC	TTGCTTCCCT	TTCCCAAGCA	GAGGTGCTCA	CTCCATGGCC	ACCGCCACCA
61	CAGGCCACACA	GGGAGTACTG	CCAGACTACT	GCTGATGTTT	TCTTAAGGCC	CAGGGAGTCT
121	CAACCAAGCTG	GTGGTGAATG	CTGCTGGCA	CGGGACCCCC	CCC	
28B (SEQ ID NO: 4)						
1	TTTATTTGT	AAATATATGT	ATTACATCCC	TAGAAAAAGA	ATCCCAGGAT	TTTCCCTCT
61	GTGTGTTTC	GTCTTGCTTC	TTCATGGTCC	ATGATGCCAG	CTGAGGTTGT	CAGTACAATG
121	AAACCAAACT	GGCGGATGG	AAGCAGATTA	TTCTGCCATT	TTTCCAGGTC	TTT
37B (SEQ ID NO: 5)						
1	GGCTGGACAT	GGGTGCCCTC	CAGTCCCTC	ATATCCCCAG	GCACACTCTG	GCCTCAGGT
61	TGCGCCTGGC	CATGTCATCT	ACCTGGAGTG	GGCCCTCCCCC	TTCTTCAGCC	TTGAATCAAA
121	AGCCACTTTG	TTAGGCGAGG	ATTTCCAGA	CCACTCATCA	CATTAAAAAA	TATTTTGAA
181	ACAAAAAA	AAAAAA				
55B (SEQ ID NO: 6)						
1	TTGACAAAGC	TGTTTATTTT	CACCAATAAA	TAGTATATGG	TGATTGGGGT	TTCTATTAT
61	AAGAGTAGTG	GCTATTATAT	GGGGTATCAT	GTGATGCTC	ATAAATAGTT	CATATCTACT
121	TAATTTGCTT	TC				
60B (SEQ ID NO: 7)						
1	GAAGAGAGTT	GTATGTACAA	CCCCAACAGG	CAAGGCAGCT	AAATGCAGAG	GGTACAGAGA
61	GATCCCGAGG	GAATT				
86B (SEQ ID NO: 8)						
1	GGATGGAAAC	ATGTAGAAGT	CCAGAGAAAA	ACAATTTTAA	AAAAAGGTGG	AAAAAGTTACG
61	GCAAACTCTGA	GATTTTCAGCA	TAAATCTTT	AGTTAGAAGT	GAGAGAAAGA	AGAGGGAGGC
121	TGGTTGCTGT	TGCACGTATC	AATAGGTTAT	C		
87B (SEQ ID NO: 9)						
1	TTCTTGATCT	TTAGAACACT	ATGAATAGGG	AAAAAGAAAA	AAACTGTTCA	AAATAAAATG
61	TAGGAGCCGT	GCTTTTGAA	TGCTTGAGTG	AGGAGCTCAA	CAAGTCTCT	CCCAAGAAAG
181	CAATGATAAA	ACTTGACAAA	A			
98B (SEQ ID NO: 10)						
1	ACCAATTTCT	AACAATTTTT	ACTGTAAAT	TTTTGGTCAA	AGTTCTAAGC	TTAATCACAT
61	CTCAAAGAAT	AGAGGCAATA	TATAGCCAT	CTTACTAGAC	ATACAGTATT	AAACTGGACT
121	GAATATGAGG	ACAAGCTCTA	GTGGTCATTA	AACCCCTCAG	AA	
110B (SEQ ID NO: 11)						
1	ACATATATTA	ACAGCAITCA	TTTGGCCAAA	ATCTACAGT	TTGTAGAATC	CTACTGTATA
61	TAAAGTGGGA	ATGTATCAAG	TATAGACTAT	GAAAGTGCAA	ATAACAAGTC	AAGGTTAGAT
121	TAACTTTTTT	TTTTTACATT	ATAAAATTAA	CTTGTTT		
118B (SEQ ID NO: 12)						
1	CCAAATTTCT	CTGGAATCCA	TCCTCOCTCC	CATCACCATA	GCCTCGAGAC	GTCAITTTCTG
61	TTTGACTACT	CCAGC				
133B (SEQ ID NO: 13)						
1	AACTAACCTC	CTCGGACCCC	TGCTCACTC	ATTACACCA	ACCAACCAAC	TATCTATAAA
61	CCTGAGCCAT	GGCCATCCCT	TATGAGCGGC	GCAGTGATTA	TAGGCTTCG	CTCTAAGATA
121	AAAT					
140B (SEQ ID NO: 14)						
1	ATTATTATTC	TTTTTTTATG	TTAGCTTAGC	CATGCAAAAT	TTACTGGTGA	AGCAGTTAAT
61	AAAACACACA	TCCCATTTGA	GGGTTTTGTA	CATTTCAGTC	CTTACAAATA	ACAAAGCAAT
121	GATAAACCCG	GCACGTCCTG	ATAGGAATTT	C		
144B (SEQ ID NO: 15)						
1	CGTGACACAA	ACATGCATTC	GTTTTATTC	TAAACAGCC	TGGTTTCTTA	AAACAATACA
61	AACAGCATGT	TCATCAGCAG	GAAGCTGGCC	GTGGGCAGGG	GGGCC	
198B* (SEQ ID NO: 16)						
1	ATAGGTTAGA	TTCTCATTC	CGGGACTAGT	TAGCTTTAAG	CACCCTAGAG	GACTAGGGTA
61	ATCTGACTTC	TCACITTCCTA	AGTTCCCTCT	TATATCCTCA	AGGTAGAAAT	GTCTATGTTT
121	TCTACTCCAA	TTTATAAATC	TATTCATAAG	TCTTTGGTAC	AAGTTACATG	ATAAAAAAGAA
181	ATGTGATTTG	TCTTCCCTTC	TTTGCACTTT	TRAAATAAAG	TATTTATCTC	CTGTCTACAG
241	TTTAAT					
212B (SEQ ID NO: 17)						
1	GTCCAGTATA	AAGGAAAGCG	TTAAGTCGGT	AAGCTAGAGG	ATTGTAAATA	TCTTTTATGT
61	CCTCTAGATA	AAACACCCGA	TTAACAGATG	TTAACCTTTT	ATGTTTTGAT	TTGCTTTAAA
121	AATGGCCTTC	TACACATTAG	CTCCAGCTAA	AAAGACACAT	TGAGAGCTTA	GAGGATAGTC
181	TCTGGAGC					
223B* (SEQ ID NO: 18)						
1	GCACTTGGAA	GGGAGTTGGT	GTGCTATTTT	TGAAGCAGAT	GTGGTGATAC	TGAAGTTGTC
61	TGTTCACTTT	CCCACTTTGT	TTGTGCTTCA	AATGATCCTT	CCTACTTTGC	TTCTCTCCAC
121	CCATGACCTT	TTTCACTGTG	GCCATCAAGG	ACTTTCTGTA	CAGCTTGTGT	ACTCTTAGGC
181	TAAGAGATGT	GACTACAGCC	TGCCCCGTGAC	TG		
241B (SEQ ID NO: 19)						
1	TGTTAGTTTT	TAGGAAGGCC	TGTCTTCTGG	GAGTGAGGTT	TATTAGTCCA	CTTCTTGGAG
61	CTAGACGTCC	TATAGTTAGT	CACTGGGGAT	GGTGAAAGAG	GGAGAAAGAG	AAGGGCGAAG
121	GGAAGGGCTC	TTTGCTAGTA	TCTCCATTTC	TAGAAAGATGG	TTTAGATGAT	AAACACAGGT
181	CTATATGAGC	ATAGTAAGGC	TGT			
32C* (SEQ ID NO: 20)						
1	CCTATTTCTG	ATCCTGACTT	TGGACAAGGC	CCTTCAGCCA	GAAGACTGAC	AAAGTCATCC
121	TCCGTCTACC	AGAGCGTGCA	CTTGTGATCC	TAAAATAAGC	TTCACTCTCG	GCTGTGCCTT
161	GGGTGGAAGG	GGCAGGATTC	TGCAGCTGCT	TTTGCAITTC	TCTTCTCTAA	TTTCATT

TABLE I-continued

PARTIAL SEQUENCES OF 32 NOVEL OC-SPECIFIC OR -RELATED EXPRESSED GENES (cDNA CLONES)					
34C (SEQ ID NO: 21)	GTGTGTTTAT	TCCTGTACAA	ATCATTACAA	AACCAAGTCT	GGGGCAGTCA
1 CCGAGCGTAG	CCATCACCCC	AGTGCAATGG	CTAGCTGCTG	GCCTTT	
61 CCGCCCCAC					
47C (SEQ ID NO: 22)	CAAAGCAGGC	AACCCCTTT	GGCACTGCTG	CCACTGGGGT	CATGGCGGTT
1 TTAGTTCACT	GGGAGGTTTC	CCCAACACCC	TCCTCTGCTT	CCCTGTGTGT	CGGGGTCTCA
61 GTGGCAGCTG	CAGAGTGA				
121 GGAGCTGACC					
65C (SEQ ID NO: 23)	TAAGAGAGAT	TTTGGTCTTA	AAGGCTTCAT	CATGAAAGTG	TACATGCATA
1 GCTGAATGTT	AATACGTGG	TATGGATGGT	TGCTTGTTTA	TTAACTAAAG	ATGTACAGCA
61 TGCAAGTGTG	TTAGAGTCCT	CTTAATATTG	ATGTCTTAAC	ACTGGGTCTG	CTTATGC
121 AACTGCCCGT					
79C (SEQ ID NO: 24)	TATGGAATCC	AGAAGGGAAA	CAAGCACTGG	ATAATTAATA	ACAGCTGGGG
1 GGCAATGCGA	GGAAACAAAG	GATATATCT	CATGGCTCOA	AATAAGAAC	AOCCTGTGG
61 AGAAATCTGG	CTGGCCAGCT	TCCCAAGAT	GTGACTCCAG	CCAGAAA	
121 CATTGCCAAC					
84C (SEQ ID NO: 25)	ACCGTCTTTA	TTCTCTCTCT	GOCTCAGAGG	TCAGGAAGGA	GGTCTGGCAG
1 GCCAGGGCGG	GGGCGCTAGT	CATCTGTGGC	AGCGAAGGTG	AAGGGACTCA	CCTTGTCCGC
61 GACCTGCAGT	TAGAATTGT	TCTGGAATTC			
121 CGTGCCCTGAG					
86C (SEQ ID NO: 26)	CACTCTGGTA	TTTTTAGTTT	AACAATATAT	GTGTTGTGTC	TTGGAAATTA
1 AACTCTTTCA	ATTCTATATG	AGCTGTCTCA	TTCTTTTTTT	AATGTCATA	TACAGTAGTA
61 GTTCATATCA	AGAATATATC	CTAATACTTT	TTAAAA		
121 TTCAATTATA					
87C (SEQ ID NO: 27)	GAAGGCCTGA	GGCCTAGGGG	CCGRGGCTGG	CCTGCGTCTC	AGTCTGGGA
1 GGATAAGAAA	CGCACAGGTT	GAGAGGGGCA	CTTCTCTTGG	CTTAGGTTGG	TGAGGATCTG
61 CGCAGCAGCC	GCCGGTGGAG	AGCCACAAA			
121 GTCCGTGTTG					
88C (SEQ ID NO: 28)	AGAGTTTGAC	CTGGAGCCGG	ATACCTACTG	CCGCTATGAC	TCGGTCAGCG
1 CTGACCTTCG	AGCGTGAGC	GACGACTCCG	GTGGGGAAAT	TCTGCGGCGA	T
61 TGTTCACCGG					
89C (SEQ ID NO: 29)	GTGGATAGTG	CTTTTGTTGA	GCAATGCTC	CCTCTTAAG	GTATAGGGC
1 ATCCCTGGCT	TGGGAGTGTG	GAACTACTAC	TTAACTGTCT	GTCCTGCTTG	GCTGTGTTA
61 TCCCTGAGTT	TGATGTTGT	GCTAACATA	AGAATAC		
121 TCGTTTCTG					
101C (SEQ ID NO: 30)	CCCTCTCCTC	CTCCATCCCC	ATACATCACC	AGGTCTAATG	TTTACAAACG
1 GGCTGGGCAAT	GGCTCTGAAO	CCAAGGGGCG	TCCGTGCCAC	GGTGGCTGTG	AGTATCTCTC
61 GTGCCAGCCC	CCCATAAGGT	TGGAGTATCT	GC		
121 CGTTAGCTTT					
112C (SEQ ID NO: 31)	CCGCGATACA	GACCCACAGA	GTGCCATCCC	TGAGAGACCA	GACCGCTCCC
1 CCAACTCCTA	CTAAAATAAA	CATGAAGCAC			
161 CAATACTCTC					
114C (SEQ ID NO: 32)	TGTCTCATGG	TGGGAAGGAA	CATGGTACAT	TTC	
1 CATGGATGAA					

*Repeated 3 times

*Repeated 2 times

Sequence analysis of the OC⁺ stromal cell⁻ cloned DNA sequences revealed, in addition to the novel sequences, a number of previously-described genes. The known genes identified (including type 5 acid phosphatase, gelatinase B, cystatin C (13 clones), Alu repeat sequences (11 clones), creatine kinase (6 clones) and others) are summarized in Table II. In situ hybridization (described below) directly demonstrated that gelatinase B mRNA is expressed in multinucleated osteoclasts and not in stromal cells. Although gelatinase B is a well-characterized protease, its expression at high levels in osteoclasts has not been previously described. The expression in osteoclasts of cystatin C, a cysteine protease inhibitor, is also unexpected. This finding has not yet been confirmed by in situ hybridization. Taken together, these results demonstrate that most of these identified genes are osteoclast-expressed, thereby confirming the effectiveness of the differential screening strategy for identifying DNA encoding osteoclast-specific or -related gene products. Therefore, novel genes identified by this method have a high probability of being OC-specific or related.

In addition, a minority of the genes identified by this screen are probably not expressed by OCs (Table II). For example, type III collagen (6 clones), collagen type I (1 clone), dermatansulfate (1 clone), and type VI collagen (1

clone) are more likely to originate from the stromal cells or from osteoblastic cells which are present in the tumor. These cDNA sequences survive the differential screening process either because the cells which produce them in the tumor in vivo die out during the stromal cell propagation phase, or because they stop producing their product in vitro. These clones do not constitute more than 5-10% of the all sequences selected by differential hybridization.

TABLE II

SEQUENCE ANALYSIS OF CLONES ENCODING KNOWN SEQUENCES FROM AN OSTEOCLASTOMA cDNA LIBRARY

Clones with Sequence Homology to Collagenase Type IV	25 total
Clones with Sequence Homology to Type 5 Tartrate Resistant Acid Phosphatase	14 total
Clones with Sequence Homology to Cystatin C	13 total
Clones with Sequence Homology to Alu-repeat Sequences	11 total
Clones with Sequence Homology to Creatine Kinase	6 total
Clones with Sequence Homology to	6 total

TABLE II-continued

SEQUENCE ANALYSIS OF CLONES ENCODING KNOWN SEQUENCES FROM AN OSTEOCLASTOMA cDNA LIBRARY	
Type III Collagen	
Clones with Sequence Homology to MHC Class I γ Invariant Chain	5 total
Clones with Sequence Homology to MHC Class II β Chain	3 total
One or Two Clone(s) with Sequence Homology to Each of the Following:	10 total
$\alpha 1$ collagen type I	
γ interferon inducible protein	
osteopontin	
Human chondroitin/dermatan sulfate	
α globin	
β glucosidase/sphingolipid activator	
Human CAPL protein (Ca binding)	
Human EST 01024	
Type VI collagen	
Human EST 00553	

Example 5—In situ Hybridization of OC-Expressed Genes

In situ hybridization was performed using probes derived from novel cloned sequences in order to determine whether the novel putative OC-specific or -related genes are differentially expressed in osteoclasts (and not expressed in the stromal cells) of human giant cell tumors. Initially, in situ hybridization was performed using antisense (positive) and sense (negative control) cRNA probes against human type IV collagenase/gelatinase B labelled with 35 S-UTP.

A thin section of human giant cell tumor reacted with the antisense probe resulted in intense labelling of all OCs, as indicated by the deposition of silver grains over these cells, but failed to label the stromal cell elements. In contrast, only minimal background labelling was observed with the sense (negative control) probe. This result confirmed that gelatinase B is expressed in human OCs.

In situ hybridization was then carried out using cRNA probes derived from 11/32 novel genes, labelled with digoxigenin UTP according to known methods.

The results of this analysis are summarized in Table III. Clones 28B, 118B, 140B, 198B, and 212B all gave positive reactions with OCs in frozen sections of a giant cell tumor, as did the positive control gelatinase B. These novel clones therefore are expressed in OCs and fulfill all criteria for OC-relatedness. 198B is repeated three times, indicating relatively high expression. Clones 4B, 37B, 88C and 98B produced positive reactions with the tumor tissue; however the signal was not well-localized to OCs. These clones are therefore not likely to be useful and are eliminated from further consideration. Clones 86B and 87B failed to give a positive reaction with any cell type, possibly indicating very low level expression. This group of clones could still be useful but may be difficult to study further. The results of this analysis show that 5/11 novel genes are expressed in OCs, indicating that ~50% of novel sequences likely to be OC-related.

To generate probes for the in situ hybridizations, cDNA derived from novel cloned osteoclast-specific or -related cDNA was subcloned into a BlueScript II SK(-) vector. The orientation of cloned inserts was determined by restriction analysis of subclones. The T7 and T3 promoters in the BlueScriptII vector was used to generate 35 S-labelled (35 S-UTP 850 Ci/mmol, Amersham, Arlington Heights, Ill.), or

UTP digoxigenin labelled cRNA probes.

TABLE III

In Situ HYBRIDIZATION USING PROBES DERIVED FROM NOVEL SEQUENCES			
Clone	Reactivity with:		
	Osteoclasts	Stromal Cells	
4B	+	+	
28B*	+	-	
37B	+	+	
86B	-	-	
87B	-	-	
88C	+	+	
98B	+	+	
118B*	+	-	
140B*	+	-	
198B*	+	-	
212B*	+	-	
Gelatinase B*	+	-	

*OC-expressed, as indicated by reactivity with antisense probe and lack of reactivity with sense probe on OCs only.

In situ hybridization was carried out on 7 micron cryostat sections of a human osteoclastoma as described previously (Chang, L.-C. et al. *Cancer Res.* 49:6700 (1989)). Briefly, tissue was fixed in 4% paraformaldehyde and embedded in OCT (Miles Inc., Kankakee, Ill.). The sections were rehydrated, postfixed in 4% paraformaldehyde, washed, and pretreated with 10 mM DTT, 10 mM iodoacetamide, 10 mM N-ethylmaleimide and 0.1 triethanolamine-HCl. Prehybridization was done with 50% deionized formamide, 10 mM Tris-HCl, pH 7.0, 1x Denhardt's, 500 mg/ml tRNA, 80 mg/ml salmon sperm DNA, 0.3M NaCl, mM EDTA, and 100 mM DTT at 45° C. for 2 hours. Fresh hybridization solution containing 10% dextran sulfate and 1.5 ng/ml 35 S-labelled or digoxigenin labelled RNA probe was applied after heat denaturation. Sections were coverslipped and then incubated in a moistened chamber at 45°-50° C. overnight. Hybridized sections were washed four times with 50% formamide, 2x SSC, containing 10 mM DTT and 0.5% Triton X-100 at 45° C. Sections were treated with RNase A and RNase T1 to digest single-stranded RNA, washed four times in 2x SSC/10 mM DTT.

In order to detect 35 S-labelling by autoradiography, slides were dehydrated, dried, and coated with Kodak NTB-2 emulsion. The duplicate slides were split, and each set was placed in a black box with desiccant, sealed, and incubated at 4° C. for 2 days. The slides were developed (4 minutes) and fixed (5 minutes) using Kodak developer D19 and Kodak fixer. Hematoxylin and eosin were used as counterstains.

In order to detect digoxigenin-labelled probes, a Nucleic Acid Detection Kit (Boehringer-Mannheim, Cat. #1175041) was used. Slides were washed in Buffer 1 consisting of 100 mM Tris/150 mM NaCl, pH 7.5, for 1 minute. 100 μ l Buffer 2 was added (made by adding 2 mg/ml blocking reagent as provided by the manufacturer) in Buffer 1 to each slide. The slides were placed on a shaker and gently swirled at 20° C.

Antibody solutions were diluted 1:100 with Buffer 2 (as provided by the manufacturer). 100 μ l of diluted antibody solution was applied to the slides and the slides were then incubated in a chamber for 1 hour at room temperature. The slides were monitored to avoid drying. After incubation with antibody solution, slides were washed in Buffer 1 for 10 minutes, then washed in Buffer 3 containing 2 mM levamisole for 2 minutes.

After washing, 100 μ l color solution was added to the slides. Color solution consisted of nitroblue/tetrazolium salt

13

(NBT) (1:225 dilution) 4.5 μ l, 5-bromo-4-chloro-3-indolyl phosphate (1:285 dilution) 3.5 μ l, levamisole 0.2 mg in Buffer 3 (as provided by the manufacturer) in a total volume of 1 ml. Color solution was prepared immediately before use.

After adding the color solution, the slides were placed in a dark, humidified chamber at 20° C. for 2-5 hours and monitored for color development. The color reaction was stopped by rinsing slides in TE Buffer.

The slides were stained for 60 seconds in 0.25% methyl green, washed with tap water, then mounted with water-based Permount (Fisher).

Example 6—Immunohistochemistry

Immunohistochemical staining was performed on frozen and paraffin embedded tissues as well as on cytospin preparations (see Table IV). The following antibodies were used: polyclonal rabbit anti-human gelatinase antibodies; Ab110 for gelatinase B; monoclonal mouse anti-human CD68 antibody (clone KP1) (DAKO, Denmark); Mol (anti-CD11b) and Mo2 (anti-CD14) derived from ATCC cell lines HB CRL 8026 and TIB 228/HB44. The anti-human gelatinase B antibody Ab110 was raised against a synthetic peptide with the amino acid sequence EALMYPMYRFTEGPPLHK (SEQ ID NO: 34), which is specific for human gelatinase B (Corcoran, M. L. et al. *J. Biol. Chem.* 267:515 (1992)).

Detection of the immunohistochemical staining was achieved by using a goat anti-rabbit glucose oxidase kit (Vector Laboratories, Burlingame Calif.) according to the manufacturer's directions. Briefly, the sections were rehydrated and pretested with either acetone or 0.1% trypsin. Normal goat serum was used to block nonspecific binding. Incubation with the primary antibody for 2 hours or overnight (Ab110:1/500 dilution) was followed by either a glucose oxidase labeled secondary anti-rabbit serum, or, in the case of the mouse monoclonal antibodies, were reacted with purified rabbit anti-mouse Ig before incubation with the secondary antibody.

Paraffin embedded and frozen sections from osteoclastomas (GCT) were reacted with a rabbit antiserum against gelatinase B (antibody 110) (Corcoran, M. L. et al. *J. Biol. Chem.* 267:515 (1992)), followed by color development with glucose oxidase linked reagents. The osteoclasts of a giant cell tumor were uniformly strongly positive for gelatinase B, whereas the stromal cells were unreactive. Control sections reacted with rabbit preimmune serum were negative. Identical findings were obtained for all 8 long bone giant cell tumors tested (Table IV). The osteoclasts present in three out of four central giant cell granulomas (GCG) of the mandible were also positive for gelatinase B expression. These neoplasms are similar but not identical to the long bone giant cell tumors, apart from their location in the jaws (Shafer, W. G. et al., *Textbook of Oral Pathology*, W. B. Saunders Company, Philadelphia, pp. 144-149 (1983)). In contrast, the multinucleated cells from a peripheral giant cell tumor, which is a generally non-resorptive tumor of oral soft tissue,

14

were unreactive with antibody (Shafer, W. G. et al., *Textbook of Oral Pathology*, W. B. Saunders Company, Philadelphia, pp. 144-149 (1983)).

Antibody 110 was also utilized to assess the presence of gelatinase B in normal bone (n=3) and in Paget's disease, in which there is elevated bone remodeling and increased osteoclastic activity. Strong staining for gelatinase B was observed in osteoclasts both in normal bone (mandible of a 2 year old), and in Paget's disease. Staining was again absent in controls incubated with preimmune serum. Osteoblasts did not stain in any of the tissue sections, indicating that gelatinase B expression is limited to osteoclasts in bone. Finally, peripheral blood monocytes were also reactive with antibody 110 (Table IV).

TABLE IV

DISTRIBUTION OF GELATINASE B IN VARIOUS TISSUES

Samples	Antibodies tested Ab 110 gelatinase B
GCT frozen (n = 2)	
giant cells	+
stromal cells	-
GCT paraffin (n = 6)	
giant cells	+
stromal cells	-
central GCG (n = 4)	
giant cells	+(%)
stromal cells	-
peripheral GCT (n = 4)	
giant cells	-
stromal cells	-
Paget's disease (n = 1)	
osteoclasts	+
osteoblasts	-
normal bone (n = 3)	
osteoclasts	+
osteoblasts	-
monocytes (cytospin)	+

Distribution of gelatinase B in multinucleated giant cells, osteoclasts, osteoblasts and stromal cells in various tissues. In general, paraffin embedded tissues were used for these experiments; exceptions are indicated.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(11) NUMBER OF SEQUENCES: 34

-continued

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 170 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
GCAAAATATCT AAGTTTATTG CTTGGAATTC TAGTGACAGC TGTGAATTT GGTGATGTCA      60
AATGTTTCTA GGTTTTTTTT AGTTTGTTTT TATTGAAAAA TTTAATTATT TATGCTATAG      120
GTGATATTCT CTTTGAATAA ACCTATAATA GAAATAGCA GCAGACAACA      170
```

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 63 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
GTGTCAACCT GCATATCCTA AAAATGTCAA AATGCTGCAT CTGTTAATG TCGGGTAGG      60
GGG                                                                    63
```

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 163 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```
CTTCCCTCTC TTGCTTCCTT TTCCCAAGCA GAGGTGCTCA CTCATGCC ACCGCCACCA      60
CAGGCCACCA GGAAGTACTG CCAGACTACT GCTGATGTTT TCTTAAGGCC CAAGGAGTCT      120
CAACCAGCTG GTGGTGAATG CTGCCTGGCA CGGGACCCCC CCC                        163
```

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 173 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```
TTTTATTTGT AAATATATGT ATTACATCCC TAGAAAAAGA ATCCCAGGAT TTTCCCTCCT      60
GTGTGTTTTT GTCTTCTTC TTCATGGTCC ATGATGCCAG CTGAGGTTGT CAGTACAATG      120
AAACCAAACT GCGGGGATGG AAGCAGATTA TTCTGCCATT TTTCCAGGTC TTT          173
```

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 197 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double

BEST AVAILABLE COPY

-continued

(D) TOPOLOGY: linear

(1) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

GGCTGGACAT GGGTGGCCTC CACGTCCCTC ATATCCCCAG GCACACTCTG GCCTCAGGTT      60
TTGCCCTGGC CATGTCATCT ACCTGGAGTG GGGCCTCCCC TTCTTCAGCC TTGAATCAAA      120
AGCCACTTTG TTAGGCGAGG ATTTCCAGAG CCACATCATC CATTAAAAAA TATTTTAAAA      180
ACAAAAAAA AAAAAAA      197

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 132 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(1) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

TTGACAAAGC TGTATTATTC CACCAATAAA TAGTATATGG TGATTGGGGT TTCTATTTAT      60
AAGAGTAGTG GCTATTATAT GGGGTATCAT GTTGATGCTC ATAAATAGTT CATATCTACT      120
TAATTTGCCT TC      132

```

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(1) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

GAAGAGAGTT OTATGTACAA CCCCACAGG CAAGGCAGCT AAATGCAAGG GGTACAGAGA      60
GATCCCGAGG GAATT      75

```

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 151 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(1) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:8:

```

GGATGGAAAC ATGTAGAAAT CCAGAGAAAA ACAATTTTAA AAAAAGGTGG AAAAGTTACG      60
GCAAACTGA GATTTCAGCA TAAATCTTT AGTTAGAAAT GAGAGAAAGA AGAGGGAGGC      120
TGOTTGCTGT TGCACGTATC AATAGGTTAT C      151

```

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 141 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(1) MOLECULE TYPE: DNA (genomic)

-continued

(1) SEQUENCE DESCRIPTION: SEQ ID NO:9:

TTCTTGATCT TTAGAACACT ATGAATAGGG AAAAAAGAAA AAAGTGTTC AATATAAATG 60
 TAGGAGCCGT GCTTTTGGAA TGCTTGAGTG AGGAGCTCAA CAAGTCCTCT CCCAAGAAAAG 120
 CAATGATAAA ACTTGACAAA A 141

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 162 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ACCCATTCT AACAATTTT ACTGTAAAT TTTGGTCAA AGTTCTAAGC TTAATCACAT 60
 CTCAAAGAAT AGAGGCAATA TATGCCCAT CTTACTAGAC ATACAGTATT AAAGTGGACT 120
 GAATATGAGG ACAAGCTCTA GTGGTCATTA AACCCCTCAG AA 162

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 157 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:11:

ACATATATTA ACAGCATTCA TTTGGCCAAA ATCTACACGT TTGTAGAATC CTAAGTGTATA 60
 TAAAGTGGGA ATGTATCAAG TATAGACTAT GAAAGTGCAA ATAACAAGTC AAGGTTAGAT 120
 TAACITTTTT TTTTACATT ATAAAATTAA CTGTGTT 157

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CCAAATTTCT CTGGAATCCA TCCTCCCTCC CATCACCATA GCCTCGAGAC GTCATTCTG 60
 TTTGACTACT CCAGC 75

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 124 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AACTAACCTC CTCGACCCC TGCCTCACTC ATTTACACCA ACCACCCAAC TATCTATAAA 60
 CCTGAGCCAT GGCCATCCCT TATGAGCGGC GCAGTGATTA TAGGCTTTCT CTCTAAGATA 120

BEST AVAILABLE COPY

-continued

AAAT

124

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 151 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```
ATTATTATTC TTTTTTATG TTAGCTTAGC CATGCAAAAT TTAAGTGTGA AGCAGTTAAT      60
AAAAACACACA TCCCATTTGAA GGGTTTTGTA CATTTCAGTC CTTACAAATA ACAAAGCAAT      120
GATAAACCCG GCACGTCCTG ATAGGAAATT C                                     151
```

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 105 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```
CGTGACACAA ACATGCATTC GTTTTATTCA TAAAAACAGCC TGGTTTCCTA AAACAATACA      60
AACAGCATGT TCATCAACAG GAAAGCTGGCC GTGGGCAGGG GGGGCC                                     105
```

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 246 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```
ATAAGTTAGA TTCTCATTCA CCGGACTAGT TAGCTTTAAG CACCCTAGAG GACTAGGGTA      60
ATCTGACTTC TCACTTCCTA AGTTCCTCT TATATCTCA AGGTAGAAAT GTCTATGTTT      120
TCTACTCCAA TTCATAAATC TATTCATAAG TCTTTGGTAC AAGTTACATG ATAAAAAGAA      180
ATGTGATTTG TCTTCCCTTC TTTGCACCTT TGAAATAAAG TATTATCTC CTCTCTACAG      240
TTTAAT                                     246
```

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 188 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:17:

```
GTCCAGTATA AAGGAAAGCG TTAAGTCGT AAGCTAGAGG ATTGTAAATA TCTTTTATGT      60
CCTCTAGATA AAACACCCGA TTAACAGATG TTAACCTTTT ATGTTTTGAT TTGCTTTAAA      120
AATGGCCTTC TACACATTAG CTCCAGCTAA AAAGACACAT TGAGAGCTTA GAGGATAGTC      180
```

-continued

TCTGGAGC

185

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 212 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GCACTTGGAA	OGGAGTTGCT	GTGCTATTTT	TGAAACAGAT	GTGGTGATAC	TGAGATTGTC	60
TGTTCACTTT	CCCCATTTGT	TTGTGCTTCA	AATGATCCTT	CCTACTTTGC	TTCTCTCCAC	120
CCATGACCTT	TTTCACTGTG	GCCATCAAAG	ACTTTCCTGA	CAGCTTGTGT	ACTCTTAGGC	180
TAAGAGATGT	GACTACAGCC	TGCCCCGTAC	TG			212

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 203 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TGTTAGTTTT	TAGGAAGGCC	TGTCTTCTGG	GAGTGAGGTT	TATTAGTCCA	CTTCTTGGAG	60
CTAGACGTCC	TATAGTTAGT	CACTGGGGAT	GGTGAAAGAG	GGAGAAGAGG	AAGGGCGAAG	120
GGAAGGGCTC	TTTGCTAGTA	TCTCCATTTT	TAGAAAGATG	TTTAGATGAT	AACCACAGGT	180
CTATATGAGC	ATAGTAAGGC	TGT				203

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 177 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CCTATTTCTG	ATCCTGACTT	TGGACAAGGC	CCTTCAGCCA	GAAGACTGAC	AAAGTCATCC	60
TCCGTCTACC	AGAGCGTGCA	CTTGATGATC	TAAAATAAGC	TTTATCTCCG	GCTGTGCCTT	120
GGGTGGAAGG	GGCAGGATTC	TCCAGCTGCT	TTTGCATTTT	TCTTCTTAAA	TTTCATT	177

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 106 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CGGAGCGTAG	GTGTGTTTAT	TCCTGTACAA	ATCATTACAA	AACCAAGTCT	GGGGCAGTCA	60
CCGCCCCCAC	CCATCACCCC	AOTGCAATGG	CTAGCTGCTG	GCCTTT		106

-continued

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 139 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:22:

```
TTAQTTCAGT CAAAGCAGGC AACCCCTTT GGCAGTCTG CCACTGCGGT CATGCCGTT      60
GTGGCAGCTG GGGAGGTTTC CCCAACACCC TCCTCTGCTT CCCTGTGTGT CCGGGTCTCA    120
GGAGCTGACC CAGAGTGGG                                     139
```

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 177 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:23:

```
GCTGAATGTT TAAGAGAGAT TTGGTCTTA AAGGCTTCAT CATGAAAGTG TACATGCATA      60
TGCAAGTGTG AATTACGTGG TATGGATGGT TGCTTGTTTA TTAAGTAAAG ATGTACAGCA    120
AACTGCCCGT TTAGAGTCCT CTTAATATTG ATGTCTAAC ACTGGGTCTG CTTATGC       177
```

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 167 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:24:

```
GGCAGTGGGA TATGAAATCC AGAAGGGAAA CAAGCACTGG ATAATTAAAA ACAGCTGGGG      60
AGAAAACTGG OGAAACAAAG GATATATCCT CATGGCTCGA AATAAGAAC ACGCCTGTGG    120
CATTGCCAAC CTGCCCAGCT TCCCCAAGAT GTGACTCCAG CCAGAAA                   167
```

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 151 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:25:

```
GCCAGGGCGG ACCGTCTTTA TTCCTCTCCT GCCTCAGAGG TCAGGAAGGA GGTCTGGCAG      60
GACCTGCAGT GGGCCCTAGT CATCTGTGGC AGCGAAGGTG AAGGGACTCA CCTTGTGGCC    120
CCTGCCTGAG TAGAAGTTGT TCTGGAATTC C                                     151
```

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

-continued

(A) LENGTH: 156 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:26:

```
A A C T C T T T C A   C A C T C T G T A   T T T T A G T T T   A A C A A T A T A T   G T G T T G T G T C   T T G G A A A T T A   60
G T T C A T A T C A   A T T C A T A T T G   A G C T G T C T C A   T T C T T T T T T T   A A T G G T C A T A   T A C A G T A G T A   120
T T C A A T T A T A   A G A A T A T A T C   C T A A T A C T T T   T T A A A A                               156
```

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 150 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:27:

```
G G A T A A G A A A   G A A G G C C T G A   G G G C T A G G G G   C C G G G G C T G G   C C T G C G T C T C   A G T C C T G G G A   60
C G C A G C A G C C   C G C A C A G G T T   G A G A G G G G C A   C T T C C T C T T G   C T T A G G T T G G   T G A G G A T C T G   120
G T C C T G G T T G   G C C G G T G G A G   A G C C A C A A A A                               150
```

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 212 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:28:

```
G C A C T T G G A A   G G G A G T T G G T   G T G C T A T T T T   T G A A G C A G A T   G T G G T G A T A C   T G A G A T T G T C   60
T G T T C A G T T T   C C C C A T T T G T   T T G T C T T C A   A A T G A T C C T T   C C T A C T T T G C   T T C T C T C C A C   120
C C A T G A C C T T   T T T C A C T G T G   G C C A T C A A G G   A C T T T C C T G A   C A G C T T G T G T   A C T C T T A G G C   180
T A A G A G A T G T   G A C T A C A G C C   T G C C C C T O A C   T G                               212
```

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 157 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(x i) SEQUENCE DESCRIPTION: SEQ ID NO:29:

```
A T C C C T G G C T   G T G G A T A G T G   C T T T T G T G T A   G C A A A T G C T C   C C T C C T T A A G   G T T A T A G G G C   60
T C C C T G A G T T   T G G G A G T G T G   G A A G T A C T A C   T T A A C T G T C T   G T C C T G C T T G   G C T G T C G T T A   120
T C G T T T T C T G   G T G A T G T T G T   G C T A A C A A T A   A G A A T A C                               157
```

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 152 base pairs
 (B) TYPE: nucleic acid

(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(* i) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GGCTGGGCAT CCCTCTCCTC CTCCATCCCC ATACATCACC AGGTCTAATG TTTACAAACG	60
GTGCCAGCCC GGCTCTGAAG CCAAGGGCCG TCCGTGCCAC GGTGGCTGTG AGTATTCCTC	120
CGTTAOCITT CCCATAAGGT TGGAGTATCT GC	152

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 90 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(* i) SEQUENCE DESCRIPTION: SEQ ID NO:31:

CCAATCCTA CCGGATACA GACCCACAGA GTGCCATCCC TGAGAGACCA GACCGCTCCC	60
CAATACTCTC CTAAATAAA CATGAAGCAC	90

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(* i) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CATGGATGAA TGTCTCATGG TGGGAAGGAA CATGGTACAT TTC	43
---	----

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2333 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(i i) MOLECULE TYPE: DNA (genomic)

(* i) SEQUENCE DESCRIPTION: SEQ ID NO:33:

AGACACCTCT GCCCTCACCA TGAGCCTCTG GCAGCCCCTG GTCCTGGTGC TCCTGGTCT	60
GGGCTGCTGC TTTGCTGCCC CCAGACAGCG CCAGTCCACC CTTGTGCTCT TCCCTGGAGA	120
CCTGAGAACC AATCTCACCG ACAGGCAGCT GGCAGAGGAA TACCTGTACC GCTATGTTA	180
CACTCGGGTG GCAGAGATGC GTGGAGAGTC GAAATCTCTG GGGCCTGCGC TGCTGCTTCT	240
CCAGAAGCAA CTCTCCCTGC CCGAGACCGG TGAAGCTGAT AGCGCCACGC TGAAGGCCAT	300
GCGAACCCCA CGGTCCGGGG TCCCAGACCT GGGCAGATTC CAAACCTTTG ACGGCGACCT	360
CAAATGACAC CACCACAACA TCACCTATTG GATCCAAAAC TACTCGGAAG ACTTGCCGCG	420
GGCGGTGATT GACGACGCTT TTGCCCCGCG CTTGCGACTG TGGAGCGCGG TGACGCCGCT	480
CACCTTCACT CCGGTGTACA GCCGGGACGC AGACATCGTC ATCCAGTTTG GTGTGCGGGA	540
GCACGGAGAC GGGTATCCCT TCGACGGGAA GGACGGGCTC CTGGCACACG CCTTTCTCTC	600
TGGCCCCGCG ATTCAGGGAG ACGCCCATTT CGACGATGAC GAGTTGTGGT CCCTGGGCAA	660

-continued

GGGCOTCGTG	GTTCCAATC	GGTTTGGAAA	CGCAGATGGC	GCGGCCTGCC	ACTTCCCCTT	720
CATCTTCGAG	GGCCGCTCCT	ACTCTGCCTG	CACCACCGAC	GGTCOCTCCG	ACGGGTTGCC	780
CTGGTGCAAT	ACCACGGCCA	ACTACGACAC	CGACGACCGG	TTTGGETTCT	GCCCCAAGCA	840
GAGACTCTAC	ACCCGGGACG	GCAATGCTGA	TGGGAAACCC	TGCCAGTTTC	CATTTCATCT	900
CCAAGGCCAA	TCCTACTCCG	CCTGCACCAC	GGACGGTCGC	TCCGACGGCT	ACCGCTGGTG	960
CGCCACCACC	GCCAACTACG	ACCGGGACAA	GCTCTTCGGC	TTCTGCCCCG	CCCGAGCTGA	1020
CTCGACGGTG	ATGGGGGGCA	ACTCGGCGGG	GGAGCTGTGC	GTCTTCCCCT	TCACTTTTCT	1080
GGGTAAGGAG	TACTCGACCT	GTACCAGCGA	GGGCGCGCGA	GATGGGCGCC	TCTGGTGCGC	1140
TACCACCTCG	AACTTTGACA	GCGACAAGAA	GTGGGCTTTC	TGCCCCGACC	AAGGATACAG	1200
TTTGTTCCTC	GTGGCGGCGC	ATGAGTTCCG	CCACGCGCTG	GGCTTAGATC	ATTCCTCAGT	1260
GCCGGAGGCG	CTCATGTACC	CTATGTACCG	CTTCACTGAG	GGGCCCCCCT	TGCATAAGGA	1320
CGACGTGAAT	GGCATCCGGC	ACCTCTATGG	TCCTCGCCCT	GAACCTGAAC	CACGGCCTCC	1380
AACCACCACC	ACACCGCAGC	CCACGGCTCC	CCCGACGGTC	TGCCCCACCG	GACCCCCCAC	1440
TGTCCACCCC	TCAGAGCGCC	CCACAGCTGG	CCCCACAGGT	CCCCCTCAG	CTGGCCCCAC	1500
AGGTCCCCCC	ACTGCTGGCC	CTTCTACGGC	CACTACTGTG	CCTTTGAGTC	CGGTGGACGA	1560
TGCCTGCAAC	GTGAACATCT	TCGACGCCAT	CGCGGAGATT	GGGAACCAAC	TGTATTTGTT	1620
CAAGGATGGG	AAGTACTGGC	GATTCTCTGA	GGGCAAGGGG	AGCCGGCCGC	AGGGCCCCCT	1680
CCTTATCGCC	GACAAGTGGC	CCGGCTGGCC	CCGCAAGCTG	GACTCGGTCT	TTGAGGAGCC	1740
GCTCTCCAAG	AAGCTTTTCT	TCTTCTCTGG	GCGCCAGGTG	TGGGTGTACA	CAGGCGCGTC	1800
GGTGCTGGGC	CCGAGGCGTC	TGGACAAGCT	GGGCTGGGA	GCCGACGTGG	CCCAGGTGAC	1860
CGGGGCCCTC	CGGAGTGGCA	GGGGGAAGAT	GCTGCTGTTT	AGCGGGCGGC	GCCTCTGGAG	1920
GTTCOACGTG	AAGGCGCAQA	TGGTGGATCC	CCGGAGCGCC	AOCGAAGTGG	ACCGGATGTT	1980
CCCCGGGGTG	CCTTTGGACA	CGCAGGACGT	CTTCCAGTAC	CGAGAGAAAG	CCTATTTCTG	2040
CCAGGACCGC	TTCTACTGGC	GCGTGAAGTC	CCGGAGTGAG	TTGAACCAGG	TGGACCAAGT	2100
GGGCTACGTG	ACCTATGACA	TCCTGCAGTG	CCCTGAGGAC	TAGGGCTCCC	GTCCTGCTTT	2160
GCAGTGCCAT	GTAATATCCC	ACTGGGACCA	ACCCTGGGGA	AAGAGCCAGT	TTGCCGGATA	2220
CAAACTGGTA	TTCTGTTCTG	GAGGAAAGGG	AGGAGTGGAG	GTGGGCTGGG	CCCTCTCTTC	2280
TCACCTTTGT	TTTTTGTGG	AGTGTCTCTA	ATAAACTTGG	ATTCTCTAAC	CTTT	2334

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 18 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: unknown

(ii) MOLECULE TYPE: peptide

(iii) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Glu Ala Leu Met Tyr Pro Met Tyr Arg Phe Thr Glu Gly Pro Pro Leu
 1 5 10 15

His Lys

We claim:

1. An isolated osteoclast-specific or -related DNA sequence, or its complementary sequence, the DNA 65 sequence comprising a nucleic acid sequence selected from the group consisting of:

a) DNA sequences set forth in the group consisting of SEQ ID NOS. 12, 14, 16 and 17, or their complementary strands; and

33

b) DNA sequences which hybridize under standard conditions to the DNA sequences defined in a).

2. A DNA construct capable of replicating, in a host cell, osteoclast-specific or -related DNA, said construct comprising:

a) a DNA sequence of claim 1; and

b) sequences, in addition to said DNA sequence, necessary for transforming or transfecting a host cell, and for replicating, in a host cell, said DNA sequence.

3. A DNA construct capable of replicating and expressing, in a host cell, osteoclast-specific or -related DNA, said construct comprising:

34

a) a DNA sequence of claim 2; and

b) sequences, in addition to said DNA sequence, necessary for transforming or transfecting a host cell, and for replicating and expressing, in a host cell, said DNA sequence.

4. A cell stably transformed or transfected with a DNA construct according to claim 3.

5. A cell stably transformed or transfected with a DNA construct according to claim 4.

* * * * *